Y-mAbs Therapeutics (Y-mAbs Therapeutics) Inventory Turnover : 0.32 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Y-mAbs Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $2.15 Mil. Y-mAbs Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2024 was $6.76 Mil. Y-mAbs Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.32.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Y-mAbs Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 287.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Y-mAbs Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.34.

Y-mAbs Therapeutics Inventory Turnover Historical Data

The historical data trend for Y-mAbs Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Inventory Turnover Chart

Y-mAbs Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory Turnover

Get a 7-Day Free Trial

0.46

1.24

1.94

Y-mAbs Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory Turnover	Get a 7-Day Free Trial															0.27	0.66	0.43	0.33	0.32

Y-mAbs Therapeutics Inventory Turnover Calculation

Y-mAbs Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory Turnover (A: Dec. 2023 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2023 )	/ (	(Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )
=	11.416	/ (	(6.702	+	5.065)	/	2 )
=	11.416	/	5.8835
=	1.94

Y-mAbs Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

	Inventory Turnover (Q: Mar. 2024 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2024 )	/ (	(Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )
=	2.147	/ (	(5.065	+	8.448)	/	2 )
=	2.147	/	6.7565
=	0.32

Y-mAbs Therapeutics (NAS:YMAB) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Y-mAbs Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	6.7565	/	2.147	*	365 / 4
	=	287.16

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Y-mAbs Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	6.7565	/	19.931
	=	0.34

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Y-mAbs Therapeutics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

230 Park Avenue, Suite 3350, New York, NY, USA, 10169

Website

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.

Executives

Thomas Gad	director, officer: President and Chairman	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg	10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg	director, 10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi	director, officer: President & CEO	230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah	officer: SVP and CMO	HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse	director, officer: EVP, CFO, Secy & Treas.	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith	officer: Senior Vice President, CCO	5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus	director, officer: Chief Executive Officer	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed	officer: Sr. VP and CSO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman	officer: Sr. VP and CCO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin	director	C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169